October Member Spotlights – Strongbridge Biopharma PLC and Aclaris Therapeutics Inc.

Strongbridge Biopharma PLC, a Trevose, Penn.-based drug company focused on rare diseases like endogenous Cushing’s syndrome, has set its IPO terms to 4.25 million shares. This could raise around million, based on the $17.93 trading price of its shares last Friday on the Norwegian Over-The-Counter System. It plans to list on the Nasdaq under ticker symbol SBBP, with BofA Merrill Lynch and Stifel serving as lead underwriters. Shareholders in the pre-revenue company include TVM (12.6% pre-IPO stake), HealthCap (11.9%), RA Capital (10.9%) and New Enterprise Associates (8.5%). www.strongbridgebio.com

Aclaris Therapeutics Inc., a Malvern, Penn.-based developer of dermatological therapeutics, has set its IPO terms to 5 million shares being offered at between $14 and $16 per share. It would have an initial market cap of around $291 million, were it to price in the middle of its range. The pre-revenue company plans to trade on the Nasdaq under ticker symbol ACRS, with Jefferies and Citigroup serving as lead underwriters. Aclaris has raised $31.5 million in VC funding from Vivo Ventures (31.2% pre-IPO stake), Fidelity Biosciences (28.5%) and Sofinova Ventures (12%). www.aclaristx.com

©2020 PACT All Rights Reserved